BioSpace News Archive

Humanetics Corporation (Humanetics) has appointed retired Rear Admiral, Colin Chinn, MD (ret. 2019) to its Medical Advisory Board.

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending March 31, 2020, and provides an update on its progress of clinical trial portfolio taking into account the impact of the Covid-19 pandemic.

Activ Surgical, a pioneering digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes and accessibility, today announced its ActivEdge platform

In an effort to fight the global COVID-19 pandemic, over 150 employees from clinical research and technology organizations have volunteered to support United Kingdom government COVID-19 testing centres.

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the protocol for the first trial from its clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) has been designated as “safe to proceed” by the US Food and Drug Administration (FDA).

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Portola Pharmaceuticals, Inc. relating to the sale of the Company to Alexion Pharmaceuticals, Inc.

BGI Genomics announced today that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 in the Canadian market.

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities charter, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at May 1, 2020

Targovax ASA announces that interim phase I clinical data from the phase I/II trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in patients with peritoneal disease originating from ovarian or colorectal cancer, will be presented at the ASCO20 Virtual Scientific conference, 29-31 May 2020.

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that it has recruited more than 150 patients in its Phase 2b GALACTIC-1 study of GB0139 in Idiopathic Pulmonary Fibrosis.